Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors in the central anxious program, conolidine modulates alternate molecular targets. A Science Developments study identified that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, wh